Plus Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Plus Therapeutics de 3.7% y 56.3% respectivamente, mientras que el BPA crecerá en un 39.9% al año.

Información clave

3.7%

Tasa de crecimiento de los beneficios

39.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	56.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	10 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Oct 07

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Sep 22

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

May 11

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

May 04

Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Feb 23

Plus Therapeutics shows positive data for ReSPECT Phase 1 clinical trial in GBM

Nov 19

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PSTV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	N/A	-41	N/A	N/A	2
12/31/2025	4	-23	N/A	-14	3
12/31/2024	3	-20	N/A	-12	2
12/31/2023	5	-13	-13	-13	N/A
9/30/2023	4	-15	-13	-13	N/A
6/30/2023	3	-17	-15	-15	N/A
3/31/2023	1	-21	-15	-15	N/A
12/31/2022	0	-20	-14	-13	N/A
9/30/2022	0	-19	-14	-13	N/A
6/30/2022	N/A	-17	-12	-11	N/A
3/31/2022	N/A	-15	-12	-11	N/A
12/31/2021	N/A	-13	-10	-10	N/A
9/30/2021	N/A	-13	-11	-11	N/A
6/30/2021	N/A	-11	-11	-11	N/A
3/31/2021	0	-10	-11	-10	N/A
12/31/2020	0	-8	-9	-8	N/A
9/30/2020	1	-4	-5	-4	N/A
6/30/2020	6	-2	-5	-4	N/A
3/31/2020	6	-2	-4	-4	N/A
12/31/2019	7	-4	-6	-6	N/A
9/30/2019	7	-7	-9	-9	N/A
6/30/2019	2	-11	-10	-10	N/A
3/31/2019	2	-9	-11	-11	N/A
12/31/2018	3	-11	-12	-12	N/A
9/30/2018	4	-18	-14	-14	N/A
6/30/2018	5	-19	-15	-15	N/A
3/31/2018	6	-24	-18	-17	N/A
12/31/2017	6	-27	-20	-18	N/A
9/30/2017	8	-23	N/A	-18	N/A
6/30/2017	9	-24	N/A	-19	N/A
3/31/2017	10	-24	N/A	-19	N/A
12/31/2016	11	-22	N/A	-20	N/A
9/30/2016	12	-20	N/A	-20	N/A
6/30/2016	12	-13	N/A	-21	N/A
3/31/2016	12	-2	N/A	-20	N/A
12/31/2015	12	-19	N/A	-20	N/A
9/30/2015	12	-24	N/A	-21	N/A
6/30/2015	11	-34	N/A	-22	N/A
3/31/2015	9	-51	N/A	-26	N/A
12/31/2014	8	-39	N/A	-30	N/A
9/30/2014	7	-42	N/A	-35	N/A
6/30/2014	9	-38	N/A	-36	N/A
3/31/2014	10	-29	N/A	-34	N/A
12/31/2013	12	-26	N/A	-35	N/A
9/30/2013	16	-20	N/A	-33	N/A
6/30/2013	15	-26	N/A	-33	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PSTV siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PSTV siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PSTV siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (56.3% al año) de PSTV crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (56.3% al año) de PSTV crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PSTV se prevé que sea elevada dentro de 3 años.

Plus Therapeutics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 50% to US$16.50

Consensus revenue estimates fall by 34%

Consensus revenue estimates fall by 28%

Consensus revenue estimates increase by 21%

Price target decreased by 13% to US$46.50

Consensus revenue estimates increase by 21%, EPS downgraded

Recent updates

Price target increased by 50% to US$16.50

Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic

Plus Therapeutics Receives Non-Compliance Update from Nasdaq

Consensus revenue estimates fall by 34%

Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Plus Therapeutics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Insufficient new directors

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.9375 million.

Plus Therapeutics, Inc. has filed a Follow-on Equity Offering.

Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting

Consensus revenue estimates fall by 28%

New major risk - Shareholder dilution

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $0.5 million worth of its shares.

Plus Therapeutics, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase

Consensus revenue estimates increase by 21%

Plus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations

Plus Therapeutics, Inc. Reports Positive Interim Updates from Two Respect Clinical Trials at SNMMI Annual Meeting

Price target decreased by 13% to US$46.50

Consensus revenue estimates increase by 21%, EPS downgraded

Consensus revenue estimates increase by 111%

Consensus revenue estimates fall by 42%

Plus Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Plus Therapeutics, Inc. Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

Plus Therapeutics Receives Second Letter from Nasdaq Regarding Minimum Bid Price Requirement

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials

High number of new and inexperienced directors

Consensus revenue estimates increase by 50%

Plus Therapeutics to Provide Update on Respect(Tm) Clinical Trials At the 27Th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Plus Therapeutics, Inc. Announces Selection of Rhenium (186Re) Obisbemeda as International Non-Proprietary Name for 186RNL

Plus Therapeutics, Inc. to Report Q3, 2022 Results on Oct 20, 2022

Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating

Plus Therapeutics, Inc. Receives Product Development Research Grant by the Cancer Prevention and Research Institute of Texas

Plus Therapeutics finalizes $17.6M grant from Texas, to get initial funds by October end

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Plus Therapeutics, Inc. Announces Summary of FDA Meeting

Plus Therapeutics, Inc. (NasdaqCM:PSTV) announces an Equity Buyback for $2 million worth of its shares.

Plus Therapeutics, Inc. Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Price target decreased to US$3.67

Plus Therapeutics GAAP EPS of -$0.24 misses by $0.02

Plus Therapeutics, Inc. to Report Q2, 2022 Results on Jul 21, 2022

Plus Therapeutics Completes Enrollment of Cohort 1 Respect-Lm Phase 1/2A Trial

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting

Plus Therapeutics Receives Non-Compliance Notice from the Nasdaq Stock Market

Price target decreased to US$4.83

Price target decreased to US$5.17

High number of new and inexperienced directors

Plus Therapeutics, Inc. to Report Q1, 2022 Results on Apr 21, 2022

Plus Therapeutics, Inc., Annual General Meeting, May 16, 2022

Plus Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$5.67

Plus Therapeutics CEO Dr. Marc Hedrick - Cancer's Hardest Problems

Does Plus Therapeutics (NASDAQ:PSTV) Have A Healthy Balance Sheet?

Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT-GBM Trial

Plus Therapeutics to proceed with eighth cohort in ReSPECT glioblastoma trial

Shareholders May Not Be So Generous With Plus Therapeutics, Inc.'s (NASDAQ:PSTV) CEO Compensation And Here's Why

Plus Therapeutics shares rise 5% on Rhenium NanoLiposome development contract

Revenue and earnings beat expectations

Full year 2020 earnings released: US$1.86 loss per share (vs US$2.77 loss in FY 2019)

Plus Therapeutics, Inc. Provides Update on Rhenium NanoLiposome (RNL™) Program

Is Plus Therapeutics (NASDAQ:PSTV) Using Debt Sensibly?

Plus Therapeutics, Inc. to Report Q4, 2020 Results on Feb 22, 2021

New 90-day high: US$3.13

Price target raised to US$6.42